PMC

Overall and CS PCa detection rates were plotted by the number of prior negative biopsy sessions stratified in 3 categories (Figure 1A-B). CDRs from the multi-institutional biopsy naïve cohort (395 patients) who underwent FBx were calculated to serve as a graphical comparison against the prior negative cohort.
A. Performance comparison of Systematic Biopsy (SBx), Fusion Biopsy (FBx) and Combined Biopsy (SBx plus FBx) for detecting all prostate cancers as a function of the number of prior biopsy sessions.
B. Performance comparison of Systematic Biopsy (SBx), Fusion Biopsy (FBx) and Combined Biopsy (SBx plus FBx) for detecting clinically significant (CS) PCa (defined as Gleason Score (GS) ≥ 3+4 =7) as a function of the number of prior biopsy sessions.

A. Forest plots of efficacy of TR versus TP prostate biopsy in Gleason score ≤6; B. Forest plots of efficacy of TR versus TP prostate biopsy in Gleason score =7; C. Forest plots of efficacy of TR versus TP prostate biopsy in Gleason score ≥8; D. Forest plots of subgroup analysis by number of biopsy cores in Gleason score ≤6 compared with the two; E. Forest plots of subgroup analysis by number of biopsy cores in Gleason score =7 compared with the two; F. Forest plots of subgroup analysis by number of biopsy cores in Gleason score ≥8 compared with the two.

(A) Size of the tumors that underwent biopsy (Biopsy) and control tumors (Control) over time after biopsy (n=6 mice). Tumor growth rate was slightly increased in mice undergoing biopsy (p < 0.05), as determined by random coefficient analysis with time included as a quadratic term. (B) Immunohistochemistry staining for Ki67 in tumors isolated from “Control mice” (control) and “Biopsy mice” (Biopsy) 8 days after biopsy. For “Biopsy mice”, an area distal to the biopsy and an area adjacent to the biopsy site within the same tumor are shown. 100x magnification. (C) Immunohistochemistry staining for CD45 in sections of tumors isolated from Control mice and Biopsy mice that had biopsy 2 days or 8 days prior to tissue harvesting. 100 × magnification.

Cost-effectiveness acceptability curves. Abbreviations: mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; QALY, quality-adjusted life years; USD, US dollars. Notes. 1. Strategy 1 (shown in blue squares): MRI targeted biopsy. Strategy 2 (shown in red triangles): MRI targeted biopsy ➔ Systematic biopsy. Strategy 3 (shown in yellow circles): MRI targeted biopsy ➔ Saturation biopsy. Strategy 4 (shown in green triangles): MRI targeted biopsy ➔ Systematic biopsy ➔ Saturation biopsy. Strategy 5 (shown in blue diamonds): Systematic biopsy ➔ MRI targeted biopsy. Strategy 6 (shown in purple ovals): Systematic biopsy ➔ MRI targeted biopsy ➔ Saturation biopsy. 2. MRI targeted biopsy refers to the administration of MRI targeted biopsy combined with systematic biopsy following a positive mpMRI